Raymond James Maintains Strong Buy on Mirum Pharmaceuticals, Lowers Price Target to $64
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Steven Seedhouse has maintained a Strong Buy rating on Mirum Pharmaceuticals (NASDAQ:MIRM) but has reduced the price target from $78 to $64.

December 19, 2023 | 9:08 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Raymond James reaffirmed a Strong Buy rating on Mirum Pharmaceuticals, although the price target was lowered from $78 to $64.
While the reduction in price target could be seen as a negative signal, the maintenance of a Strong Buy rating by Raymond James suggests that the analyst still sees significant upside potential in the stock. The mixed signals could lead to a neutral short-term impact on the stock price as investors weigh the lower price target against the continued strong buy recommendation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100